Bioage Labs vs Relay Therapeutics
Relay Therapeutics is the larger business, with $15.4m of revenue in fiscal 2025 against $9.0m for Bioage Labs (1.7 times as much). Bioage Labs kept more of each dollar of sales as profit: a net margin of -896.1% against -1800.6%. Relay Therapeutics carries less debt relative to equity (0.0% against 1.0%).
| Latest fiscal year | Bioage LabsBIOA, 2025 | Relay TherapeuticsRLAY, 2025 |
|---|---|---|
| Revenue | $9.0m | $15.4m |
| Revenue growth | — | 53.4% |
| Net income | −$80.6m | −$276m |
| Operating margin | -1031.5% | -1971.6% |
| Net margin | -896.1% | -1800.6% |
| Return on equity | -27.1% | -41.1% |
| Free cash flow | −$82.3m | −$236m |
| Cash | $189m | $84.0m |
| Total debt | $2.6m | $0 |
| Debt to equity | 1.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 62 | 192 |
| Market value | $266m | $3.78bn |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 13 sales | 0 buys, 40 sales |